Varied Response of Spontaneous Tumors to Antiangiogenic Agents
- 1.4k Downloads
Since conventional therapies are directly dependent on the supply of either drugs or oxygen, a key question is whether antiangiogenic agents produce detrimental effects on tumor vascular function, thus compromising combination therapies. A second question is whether experimental results based on fast-growing, transplanted tumors mimic those in slowly developing spontaneous tumors, which may be more representative of response in human primary tumors. To investigate changes in tumor pathophysiology, three antiangiogenic agents were compared: a) endostatin, b) anti-VEGFR-2 (DC101), and c) celecoxib. Total blood vessels were identified using anti-CD31, perfused vessels using DiOC7, and hypoxia by EF5 uptake. Although individual tumor growth rates varied substantially, DC101 produced the most striking inhibition. DC101 increased total and perfused vessel spacing as well as overall hypoxia, while endostatin increased total vessel spacing, and hypoxia and celecoxib had no marked effects. These results reinforce the idea that pathophysiological changes in spontaneous tumors are in general reflective of response in transplanted tumors. Furthermore, although DC101 inhibited growth in roughly half of the spontaneous tumors, the remaining tumors were unaffected. A key focus of future studies will be to investigate the underlying rationale for the widely varying antiangiogenic response among tumors that outwardly appear so similar.
KeywordsTumor Hypoxia Antiangiogenic Agent Spontaneous Tumor Untreated Tumor Tumor Oxygenation
Unable to display preview. Download preview PDF.
- 5.C. J. Bruns, M. Shrader, M. T. Harbison, C. Portera, C. C. Solorzano, K. W. Jauch, D. J. Hicklin, R. Radinsky, and L. M. Ellis, Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice, Int. J. Cancer 102, 101–108 (2002).PubMedCrossRefGoogle Scholar
- 13.K. Boggio, E. Di Carlo, S. Rovero, F. Cavallo, E. Quaglino, P. L. Lollini, P. Nanni, G. Nicoletti, S. Wolf, P. Musiani, and G. Forni, Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice, Cancer Res. 60, 359–364 (2000).PubMedGoogle Scholar
- 18.N. N. Hanna, S. Seetharam, H. J. Mauceri, M. A. Beckett, N. T. Jaskowiak, R. M. Salloum, D. Hari, M. Dhanabal, R. Ramchandran, R. Kalluri, V. P. Sukhatme, D. W. Kufe, and R. R. Weichselbaum, Antitumor interaction of short-course endostatin and ionizing radiation, Cancer J. 6, 287–293 (2000).PubMedGoogle Scholar
- 19.M. Prewett, J. Huber, Y. W. Li, A. Santiago, W. O’Connor, K. King, J. Overholser, A. Hooper, B. Pytowski, L. Witte, P. Bohlen, and D. J. Hicklin, Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors, Cancer Res. 59, 5209–5218 (1999).PubMedGoogle Scholar
- 20.N. Hansen-Algenstaedt, B. R. Stall, T. P. Padera, D. E. J. G. Dolmans, D. J. Hicklin, D. Fukumura, and R. K. Jain, Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy, Cancer Res. 60, 4556–4560 (2000).PubMedGoogle Scholar